

**Table S1.** Summary of the demographic data of the population analysed in this study, already analysed in the previous clinical trial (J Allergy Clin Immunol 2019;144:216-23). P: Placebo; Ld: Low dose; Hd: High dose; MI: Mild Intermittent; SI: Severe Intermittent; MP: Mild Persistent; SP: Moderate/Severe Persistent; WA: Without asthma; I: Intermittent.

Group	Age (Mean/Median)	<18 (%)	Males (%)	Rhinitis (%)				Asthma (%)				Immunoglobulins		Wheal area	
				MI	SI	MP	SP	WA	I	MP	SP	IgE	IgG4	<i>A. alternata</i>	Alt a 1
<b>P</b>	23.4/21	66.7	40	0	6.7	13.3	80	46.7	6.7	20	26.7	10.5	36.5	46.1	51.5
<b>Ld</b>	22.7/22	45	40	0	5	20	75	30	35	20	15	14.2	30.5	43.5	50.1
<b>Hd</b>	20.4/18	62.1	41.4	3.4	10.3	24.1	62.1	31	27.6	24.1	17.2	15.9	63.9	43.3	41.6
<b>Total</b>	21.7/19.5	57.8	40.6	1.6	7.8	20.3	57.8	34.4	25	21.9	18.8	15	50.5	43.8	46.4